ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT.
Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details:
France: +33 0805102207
Germany: +49 0800-6647650
Italy: +39 800897553
Switzerland +41 0800-002063
United Kingdom +44 08082389064
United States +1 877-317-6789
International Toll Free +1 412-317-6789
Event Title: Spexis AG – Business Update Conference Call
The conference call will also be available via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g
After the call, a replay of the webcast will be available via the above link.
About Spexis
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.
For further information please contact:
For Investors:
Hernan Levett
Chief Financial Officer
Spexis AG.
+41 61 567 16 00
IR@spexisbio.com
Or
Stephen Jasper
Managing Director
Gilmartin Group
stephen@gilmartinir.com
For Media:
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch
Physicians, researchers, and partner institutions across Europe aim to deliver innovative, personalized therapies more quickly…
Peer reviewed studies suggest molecular hydrogen may help protect memory, sharpen focus, and support long-term…
SAN ANTONIO--(BUSINESS WIRE)--#FutureOfHealthcare--As healthcare organizations contend with rising financial pressures, widespread burnout, and declining patient…
As EHDS interconnects EU systems, hospitals call for patch SLAs, SBOM/VEX transparency, and baseline API…
Treatment follows recent Food and Drug Administration approval of the SetPoint System for treatment of…
Treatment follows recent Food and Drug Administration approval of the SetPoint System for treatment of…